nach oben

Immunologic Research

Erschienen in:

19.12.2018 | Original Article

Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels

verfasst von: Manca Ogrič, Polona Žigon, David Drobne, Borut Štabuc, Snezna Sodin-Semrl, Saša Čučnik, Sonja Praprotnik

Erschienen in: Immunologic Research | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

By monitoring serum concentrations of infliximab (IFX) and adalimumab (ADL) and levels of their antibodies in patients with inflammatory diseases, clinicians can adjust dose and increase safety and effectiveness of treatment. The aim was to develop and validate in-house enzyme-linked immunosorbent assays (ELISAs) for IFX and ADL, together with anti-IFX and anti-ADL ELISAs for routine detection and further analysis with acid dissociation of immune complexes. Furthermore, the objectives were to compare in-house assays with commercial ELISAs and reporter gene assays (RGAs) and to determine cross-reactivity between original Remicade®/Remsima™ and their antibodies. In-house ELISAs were validated (imprecision, accuracy among other criteria) and compared with commercial apDia ELISAs and RGAs. Correlation coefficients, intraclass correlation coefficients, agreement, and bias were calculated. All in-house ELISAs gave precise and repeatable results. The immune complexes between IFX and anti-IFX were found in 3% of samples, while complexes between ADL and anti-ADL were found in 14% of samples. Significant correlations were found between in-house and apDia ELISAs and RGA for IFX, ADL, anti-IFX, and anti-ADL results. Remicade®, Remsima™, and their antibodies could be accurately measured with either apDia or in-house IFX and anti-IFX ELISAs. Accurate and precise in-house ELISAs, highly comparable with commercial ELISAs and RGAs, were developed and validated for routine analysis of samples of patients treated with IFX (Remicade® or Remsima™) or ADL providing substantial cost benefit. Complex dissociation identified samples with anti-IFX-IFX (3%) and anti-ADL-ADL (14%) complexes indicating the benefit of adding acid dissociation to therapeutic drug monitoring of IFX and ADL.

McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19. https://doi.org/10.1056/NEJMra1004965.CrossRefPubMed

Ambarus C, Yeremenko N, Tak PP, Baeten D. Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory? Curr Opin Rheumatol. 2012;24(4):351–8. https://doi.org/10.1097/BOR.0b013e3283534df4.CrossRefPubMed

Barnas JL, Ritchlin CT. Etiology and pathogenesis of psoriatic arthritis. Rheum Dis Clin N Am. 2015;41(4):643–63. https://doi.org/10.1016/j.rdc.2015.07.006.CrossRef

Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):3–10. https://doi.org/10.1016/j.autrev.2013.06.004.CrossRef

Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12(1):49–62. https://doi.org/10.1038/nrrheum.2015.169.CrossRefPubMed

Anderson DL. A new age in rheumatoid arthritis treatment. Am J Nurs. 2004;104(2):60–8.CrossRefPubMed

Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–79. https://doi.org/10.1016/j.pharmthera.2007.10.001.CrossRefPubMed

Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, et al. 3. EUROPEAN Evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 2: surgical management and special situations. J Crohn's Colitis. 2017;11(2):135–49. https://doi.org/10.1093/ecco-jcc/jjw169.

Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6(10):991–1030. https://doi.org/10.1016/j.crohns.2012.09.002.CrossRefPubMed

10.

Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010;69(6):976–86. https://doi.org/10.1136/ard.2009.126573.CrossRefPubMed

11.

Mantzaris GJ. Anti-TNFs: originators and biosimilars. Dig Dis (Basel, Switzerland). 2016;34(1–2):132–9. https://doi.org/10.1159/000443128.CrossRef

12.

Pisupati K, Benet A, Tian Y, Okbazghi S, Kang J, Ford M, et al. Biosimilarity under stress: a forced degradation study of Remicade(R) and Remsima. mAbs. 2017;9:1–13. https://doi.org/10.1080/19420862.2017.1347741.CrossRef

13.

Yoo DH, Oh C, Hong S, Park W. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product. Expert Rev Clin Immunol. 2015;11(Suppl 1):S15–24. https://doi.org/10.1586/1744666x.2015.1090314.CrossRefPubMed

14.

Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, et al. Appropriateness of testing for anti-tumor necrosis factor agent and antibody concentrations, and interpretation of results. Clin Gastroenterol Hepatol. 2016;14(9):1302–9. https://doi.org/10.1016/j.cgh.2016.05.010.CrossRefPubMed

15.

Baert F, Noman M, Vermeire S, Van Assche G, G DH, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–8. https://doi.org/10.1056/NEJMoa020888.CrossRefPubMed

16.

Bendtzen K. Immunogenicity of anti-TNF-α biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection. Front Immunol. 2015;6. https://doi.org/10.3389/fimmu.2015.00109.

17.

van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. J Immunol Methods. 2010;362(1–2):82–8. https://doi.org/10.1016/j.jim.2010.09.005.CrossRefPubMed

18.

Hart MH, de Vrieze H, Wouters D, Wolbink G-J, Killestein J, de Groot ER, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods. 2011;372(1–2):196–203. https://doi.org/10.1016/j.jim.2011.07.019.CrossRefPubMed

19.

Van Stappen T, Brouwers E, Vermeire S, Gils A. Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay. Drug Test Anal. 2017;9(2):243–7. https://doi.org/10.1002/dta.1968.CrossRefPubMed

20.

Ogric M, Tercelj M, Praprotnik S, Tomsic M, Bozic B, Sodin-Semrl S, et al. Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits. Immunol Res. 2017;65(1):172–85. https://doi.org/10.1007/s12026-016-8824-8.CrossRefPubMed

21.

Darrouzain F, Bian S, Desvignes C, Bris C, Watier H, Paintaud G, et al. Immunoassays for measuring serum concentrations of monoclonal antibodies and anti-biopharmaceutical antibodies in patients. Ther Drug Monit. 2017;39(4):316–21. https://doi.org/10.1097/ftd.0000000000000419.CrossRefPubMed

22.

Wang SL, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods. 2012;382(1–2):177–88. https://doi.org/10.1016/j.jim.2012.06.002.CrossRefPubMed

23.

Lallemand C, Kavrochorianou N, Steenholdt C, Bendtzen K, Ainsworth MA, Meritet JF, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists. J Immunol Methods. 2011;373(1–2):229–39. https://doi.org/10.1016/j.jim.2011.08.022.CrossRefPubMed

24.

Bian S, Ferrante M, Gils A. Validation of a drug-resistant anti-adalimumab antibody assay to monitor immunogenicity in the presence of high concentrations of adalimumab. AAPS J. 2017;19(2):468–74. https://doi.org/10.1208/s12248-016-0018-8.CrossRefPubMed

25.

Van Stappen T, Brouwers E, Tops S, Geukens N, Vermeire S, Declerck PJ, et al. Generation of a highly specific monoclonal anti-infliximab antibody for harmonization of TNF-coated infliximab assays. Ther Drug Monit. 2015;37(4):479–85. https://doi.org/10.1097/ftd.0000000000000162.CrossRefPubMed

26.

Bian S, Stappen TV, Baert F, Compernolle G, Brouwers E, Tops S, et al. Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays. J Pharm Biomed Anal. 2016;125:62–7. https://doi.org/10.1016/j.jpba.2016.03.029.CrossRefPubMed

27.

CLSI (2014) Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline - Third Edition. CLSI document EP05-A3. Clinical and Laboratory Standards Insitute,

28.

Van Stappen T, Billiet T, Vande Casteele N, Compernolle G, Brouwers E, Vermeire S, et al. An optimized anti-infliximab bridging enzyme-linked immunosorbent assay for harmonization of anti-infliximab antibody titers in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21(9):2172–7. https://doi.org/10.1097/mib.0000000000000434.CrossRefPubMed

29.

Gils A, Vande Casteele N, Poppe R, Van de Wouwer M, Compernolle G, Peeters M, et al. Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization. Ther Drug Monit. 2014;36(5):669–73. https://doi.org/10.1097/ftd.0000000000000074.CrossRefPubMedPubMedCentral

30.

Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–1329.e1323. https://doi.org/10.1053/j.gastro.2015.02.031.CrossRefPubMed

31.

Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11–12):1037–53. https://doi.org/10.1111/apt.14368.CrossRefPubMed

32.

Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7(7):586–9. https://doi.org/10.1016/j.crohns.2013.03.011.CrossRefPubMed

33.

Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106(4):685–98. https://doi.org/10.1038/ajg.2011.103.CrossRefPubMed

34.

Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017;12(4):e0175207. https://doi.org/10.1371/journal.pone.0175207.CrossRefPubMedPubMedCentral

35.

Vande Casteele N, Feagan BG, Gils A, Vermeire S, Khanna R, Sandborn WJ, et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014;16(4):378. https://doi.org/10.1007/s11894-014-0378-0.CrossRefPubMed

36.

Gils A, Van Stappen T, Dreesen E, Storme R, Vermeire S, Declerck PJ. Harmonization of infliximab and anti-infliximab assays facilitates the comparison between originators and biosimilars in clinical samples. Inflamm Bowel Dis. 2016;22(4):969–75. https://doi.org/10.1097/mib.0000000000000709.CrossRefPubMed

37.

Schmitz EM, van de Kerkhof D, Hamann D, van Dongen JL, Kuijper PH, Brunsveld L, et al. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits. Clin Chem Lab Med. 2016;54(7):1211–9. https://doi.org/10.1515/cclm-2015-0987.CrossRefPubMed

38.

Bloem K, van Leeuwen A, Verbeek G, Nurmohamed MT, Wolbink GJ, van der Kleij D, et al. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods. 2015;418:29–38. https://doi.org/10.1016/j.jim.2015.01.007.CrossRefPubMed

39.

Vande Casteele N, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther. 2012;36(8):765–71. https://doi.org/10.1111/apt.12030.CrossRefPubMed

40.

van Bezooijen JS, Koch BC, van Doorn MB, Prens EP, van Gelder T, Schreurs MW. Comparison of three assays to quantify infliximab, adalimumab, and etanercept serum concentrations. Ther Drug Monit. 2016;38(4):432–8. https://doi.org/10.1097/ftd.0000000000000310.CrossRefPubMed

41.

Steenholdt C, Ainsworth MA, Tovey M, Klausen TW, Thomsen OO, Brynskov J, et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn’s disease. Ther Drug Monit. 2013;35(4):530–8. https://doi.org/10.1097/FTD.0b013e31828d23c3.CrossRefPubMed

42.

Lazar-Molnar E, Delgado JC. Immunogenicity assessment of tumor necrosis factor antagonists in the clinical laboratory. Clin Chem. 2016;62(9):1186–98. https://doi.org/10.1373/clinchem.2015.242875.CrossRefPubMed

Titel: Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels
verfasst von: Manca Ogrič
Polona Žigon
David Drobne
Borut Štabuc
Snezna Sodin-Semrl
Saša Čučnik
Sonja Praprotnik
Publikationsdatum: 19.12.2018
Verlag: Springer US
Erschienen in: Immunologic Research / Ausgabe 6/2018
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-018-9050-3

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels

Abstract

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Update HNO

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Expression of human REG family genes in inflammatory bowel disease and their molecular mechanism

The link between schizophrenia and hypothyroidism: a population-based study

Altered expression of regulatory molecules in the skin of psoriasis

Tuftsin phosphorylcholine—a novel compound harnessing helminths to fight autoimmunity

Autonomic dysfunction and HPV immunization: an overview

Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Update HNO